Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Alluminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer by delivering our innovative treatments as quickly and safely as possible to as many patients all over the world as possible. The company has locations in 6 countries, including the United States, where it is headquartered, Japan, Taiwan, the Netherlands, Switzerland and India. For more information, visit www.rakuten-med.com.
Location: United States
Employees: 201-500
Total raised: $285M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | ABC Partne... | abc-partne... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.03.2024 | Series E | $119M | - |
| 02.08.2021 | Series D | $166M | - |
Mentions in press and media 22
| Date | Title | Description |
| 02.04.2026 | LOTTE HOLDINGS Healthcare and Biopharmaceutical CVC Announces Investment in Rakuten Medical, Inc. | LOTTE HOLDINGS Healthcare and Biopharmaceutical CVC Announces Investment in Rakuten Medical, Inc. Edit Release Delete Release TOKYO, JAPAN, April 2, 2026 /EINPresswire.com/ -- LOTTE HOLDINGS, CO., LTD. (Tokyo, Japan; CEO: Genichi Tamatsuka,... |
| 14.01.2026 | Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program | SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Franc... |
| 07.01.2026 | Rakuten lights path to 2028 FDA filing with fresh $100M raise | Rakuten Medical has added to its tally of megarounds, pocketing another $100 million to push its lead light-based cancer therapy toward a targeted FDA approval filing in 2028. San Diego-based Rakuten, which takes its name from a Japanese te... |
| 07.01.2026 | Rakuten Medical Raises $100M in Series F Funding | Rakuten Medical, a San Diego, CA-based biotechnology company developing and commercializing its proprietary Alluminox platform-based photoimmunotherapy, raised $100M in Series F funding. The round consisted of $70M in new capital and the co... |
| 19.03.2024 | The Japanese Head and Neck Cancer Society and Rakuten Medical will co-sponsor the disease awareness event “Rakuten Medical Head and Neck Cancer Conquering Day” during the Vissel Kobe official game on ... | - |
| 19.03.2024 | The Japanese Head and Neck Cancer Society and Rakuten Medical will co-sponsor the disease awareness event “Rakuten Medical Head and Neck Cancer Conquering Day” during the Vissel Kobe official game on ... | The Japanese Head and Neck Cancer Society and Rakuten Medical will hold a disease awareness event “Rakuten Medical” at the Vissel Kobe official game on May 15th. Co-hosted “Head and Neck Cancer Conquering Day” and invited 25 groups of 50 pe... |
| 11.03.2024 | Rakuten Medical Secures $119M in Series E Funding | Rakuten Medical, a biotechnology company focused on precision therapies for cancer treatment, has successfully raised $119M in a Series E funding round. The funding was provided by Hikma, Mizuho Bank, Dai-ichi Life, SBI Group, Rakuten Group... |
| 07.03.2024 | Rakuten Medical Gets $119M In Series E | Rakuten medical, a company developing precision therapies for treating cancer, has raised $119M in a Series E funding round. The company said the new funding came from Hikma, a global pharmaceutical company, and Mizuho Bank and Dai-ichi Lif... |
| 07.03.2024 | Rakuten Medical Closes $119M Series E Financing | Rakuten Medical, a San Diego, CA-based biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, raised $119M in Series E funding. The round, including $45M in new... |
| 06.03.2024 | Rakuten Medical Completes $119M Series E round to continue development of Alluminox Platform | - |
Show more